The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 ...

OPSUMIT -- indicated to delay disease progression and reduced hospitalizations in pulmonary arterial hypertension -- now available to patients SOUTH SAN FRANCISCO - 4 November 2013 - Actelion (ATLN.VX ...

OPSUMIT (macitentan) tablets Actelion announced that the FDA has approved Opsumit (macitentan) tablets for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Actelion ...

We note that Actelion is evaluating Opsumit for the treatment of patients suffering from pulmonary arterial hypertension (:PAH). The results from the trial (n=742) showed that the risk of a ...

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that ...

Actelion is on course to further extend its pulmonary arterial hypertension (PAH) franchise and gain European approval for Opsumit (macitentan). The long-term PAH treatment, which was last week ...

ZURICH (Reuters) - Big U.S. pharmacy chain CVS Health's move to jettison an Actelion drug from a list of covered medications is not expected to have a "meaningful impact" on the Swiss biotechnology ...

Actelion Ltd. ( ALIOF) announced that its pulmonary arterial hypertension (PAH) drug, Opsumit, has been approved in the Switzerland. The Swiss regulatory body, SwissMedic, approved Opsumit for ...

Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary ...

Actelion Ltd ( ALIOF) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its pulmonary arterial hypertension (PAH) drug, Opsumit. Actelion is looking to ...

Add Yahoo as a preferred source to see more of our stories on Google. The CVS logo is seen at one of their stores in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly By Paul Arnold and ...